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The aim of the present study was to assess the effects of an anticholinesterase agent, pyridostigmine bromide (Pyrido), on
experimental chronic Chagas heart disease in mice. To this end, male C57BL/6J mice noninfected (control:Con) or chronically
infected (5 months) with Trypanosoma cruzi (chagasic:Chg) were treated or not (NT) with Pyrido for one month. At the end
of this period, electrocardiogram (ECG); cardiac autonomic function; heart histopathology; serum cytokines; and the presence
of blood and tissue parasites by means of immunohistochemistry and PCR were assessed. In NT-Chg mice, significant changes
in the electrocardiographic, autonomic, and cardiac histopathological profiles were observed confirming a chronic inflammatory
response. Treatment with Pyrido in Chagasic mice caused a significant reduction of myocardial inflammatory infiltration, fibrosis,
and hypertrophy, which was accompanied by a decrease in serum levels of IFN𝛾with no change in IL-10 levels, suggesting a shift of
immune response toward an anti-inflammatory profile. Lower nondifferent numbers of parasite DNA copies were observed in both
treated and nontreated chagasic mice. In conclusion, our findings confirm themarked neuroimmunomodulatory role played by the
parasympathetic autonomic nervous system in the evolution of the inflammatory-immune response toT. cruzi during experimental
chronic Chagas heart disease in mice.
1. Introduction
Chagas disease, also known as American Trypanosomiasis,
an endemic parasitic disease caused by a flagellate protozoan
(Trypanosoma cruzi), is highly prevalent throughout Latin
America. Its major clinical manifestation is the chronic cha-
gasic cardiomyopathy (CCC), which affects 1/3 of the chron-
ically infected patients and may present severe symptoms
and signs, such as congestive heart failure, thromboembolic
phenomena, cardiac arrhythmias, and sudden death [1–4].
Pathological processes in the heart include mononuclear
inflammatory infiltration, focal myocarditis, epicarditis, and
neuroganglionitis, associated with variable focal fibrosis and
a paucity of parasites, which is poorly correlatedwithmyocar-
dial inflammatory infiltration [2, 4].
The pathogenesis of CCC includes the balance between
parasite invasiveness and the host immune response, par-
ticularly the Th1/Th2 balance, which affects the resis-
tance/susceptibility to T. cruzi infection [5–7]. Even though
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an imbalanced, excessive production ofTh1 proinflammatory
cytokines is critical to control of the parasite levels in blood
and tissue [8], this type of response can also be capable of
destroying functional cardiomyocytes [8] and intracardiac
autonomic neurons [2, 4, 9]. This autonomic denervation,
involving mainly parasympathetic postganglionic neurons
causes a marked cardiac autonomic dysfunction [2, 4, 9–11],
which may be involved in initiating life-threatening cardiac
arrhythmias and sudden death [2, 4]. Curiously, this vagal
parasympathetic autonomic dysfunction is strongly associ-
ated with inflammatory infiltration and immune activation
not only in Chagas heart disease but also in other types of
cardiopathy [12–15].
Although these data support a direct role of the immune
system in mediating both cardiac and autonomic nervous
disturbances, recent data indicate that changes in the auto-
nomic nervous system also affect the pattern of immune
response and inflammation in several cardiac and noncardiac
disease states [15–17], including Chagas disease [18]. Both the
sympathetic and parasympathetic branches of the autonomic
nervous system can exert substantial modulatory effects on
the immune response, mainly by inhibiting the Th1 response
profile [17, 19–21]. This new evidence also indicates that
cardiac sympathetic and particularly parasympathetic auto-
nomic denervation/dysfunction may also contribute to an
increased inflammatory response and possibly to enhanced
parasite elimination [22]. Data from our laboratory collected
in the context of acute Chagas disease in mice has recently
confirmed that cardiac autonomic denervation/dysfunction
might contribute to increased inflammation [18].
Taking into account the concepts described above,
new therapies based on manipulations of vagal neuroim-
munomodulation of the heart may be beneficial for treating
heart diseases in general and chronic chagasic cardiomyopa-
thy in particular [17, 23]. For example, therapeutic approaches
for increasing cardiac vagal function, thereby potentiating or
stimulating the vagal anti-inflammatory reflex, might have
a positive impact on chronic chagasic cardiomyopathy. In
fact, for other cardiopathies, these strategies, in both an
experimental and clinical context, including chronic electric
vagal stimulation [24] or pharmacological potentiation [25],
have successfully improved cardiac outcomes.
Pyridostigmine bromide, an anticholinesterasic agent
that has been used for many years to treatmyasthenia gravis,
exhibits protective cardiovascular effects during short-term
administration that lead to a reduction of cardiovascular risk
markers and an improvement of autonomic dysfunction [26,
26, 27, 27–29]. By potentiating vagal parasympathetic func-
tion, this compound is thought to provoke sinus bradycardia,
to reduce AV nodal conduction and the refractory period
of action potentials and to increase the cardiac excitation
threshold, among other direct cardiac effects. It is also
believed that pyridostigmine bromide, via potentiation of the
cholinergic anti-inflammatory pathway, causes a reduction
in myocardial inflammation and fibrosis associated with
an improvement in cardiac hypertrophy and remodeling.
However, there have been no reports regarding the effects
of pyridostigmine bromide on the chronic phase of Chagas
heart disease.
Therefore, the main aim of the present study was to
evaluate the effects of cholinergic potentiation with the anti-
cholinesterase agent pyridostigmine bromide on electrocar-
diographical, cardiac autonomic, histological (inflammatory
infiltration and fibrosis), immunological, and parasitological
parameters in C57BL/6j mice infected with the Romildo
strain of Trypanosoma cruzi during the chronic phase of
Chagas heart disease.
2. Methods
All experiments were performed onwild-type C57BL/6jmice
obtained from the animal facility of the Department of
Physiology of Triangulo Mineiro Federal University, Uber-
aba, MG. All animals were males, weighed 20–30 g, and
were maintained in the animal facility of the Department
of Physiology at the Triangulo Mineiro Federal University
on a rodent diet (Nuvilab CR1, Nuvital Nutrientes Ltda,
Curitiba, PR, Brazil) andwere givenwater ad libitum until the
beginning of the experimental protocols. All the experiments
were carried out according to the “Principles of Laboratory
Animal Care” formulated by the National Society forMedical
Research, England, and “The Guide for the Care and Use of
Laboratory Animals” published by the US National Institutes
of Health (NIH publication number 85-23, revised in 1996).
All procedures were also submitted to and approved by the
Commission for Ethics in the Use of Animals in Research of
the Triangulo Mineiro Federal University.
2.1. Parasite Inoculation. To induce experimental Chagas dis-
ease, mice were intraperitoneally inoculated with 15,000 try-
pomastigote forms of the Romildo strain of T. cruzi. An addi-
tional set of animals matched for gender and weight received
intraperitoneal injections of the vehicle, and these were des-
ignated as the control noninfected group. After inoculation,
all of the animals were observed at least twice daily to
monitor their general state and to assess mortality during
the acute phase. On the 12th day after inoculation, levels of
parasitemia were measured by the microhematocrit method
for the peripheral tail blood of all inoculated animals, accord-
ing to Brenner’s technique [30], to confirm infection. All
subsequent surgical procedures and experimental protocols
were performed at the 5th and 6th months of infection,
during the chronic phase of infection, which is characterized
by light tissue invasion and low mortality.
2.2. Experimental Groups. The experimental groups were
divided according to the presence of Chagas disease and the
administration of pyridostigmine bromide during the month
from the 5th to the 6thmonth of observation (chronic phase),
as described below. The numbers of animals used in each
group are indicated in the Results section. The following
groups were investigated:
Group I—Con-NT: wild-type C57BL/6j mice were inject-
edwith vehicle as a control (Con), not treated (NT)with pyri-
dostigmine bromide and evaluated after sixmonths at the end
of the observation period;
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Group II—Con-Pyrido: wild-type C57BL/6j were inject-
ed with vehicle as a control (Con) and treated with 30mg/kg
pyridostigmine bromide (Pyrido), an anticholinesterase
agent, dissolved in tap water, for 30 days from the 5th to the
6th month of observation;
Group III—Chg-NT:wild-typeC57BL/6jmicewere inoc-
ulated with 15,000 trypomastigote forms of the Romildo
strain of T. cruzi (Chg), not treated (NT) with pyridostigmine
bromide and evaluated after six months at the end of the
observation period;
Group IV—Chg-Pyrido: wild-type C57BL/6j mice were
inoculated with 15,000 trypomastigote forms of the Romildo
strain of T. cruzi (Chg) and treated with 30mg/kg pyridostig-
mine bromide (Pyrido), an anticholinesterase agent, dis-
solved in tap water, for 30 days from the 5th to the 6th month
of observation.
The solution drinking volume was monitored daily, and
the pyridostigmine bromide concentration (approximately
0.084mg/mL) was adjusted daily according to the drinking
volume to maintain a daily mean ingested dose of 30mg/kg.
2.3. Conventional Electrocardiographic (ECG) Monitoring in
AnesthetizedMice. Immediately prior to inoculation (ECG1),
at the 5th (ECG2, immediately prior to the pyridostigmine
bromide treatment) and at the 6th months of observation
(ECG3, at the end of the experimental protocol, prior to the
surgical procedures), all of the animals were submitted to a
conventional ECG study under tribromoethanol (250mg/kg,
i.p.) anesthesia. Needle electrodes were placed under the
skin to record the conventional bipolar limb leads (I, II,
and III), the unipolar limb leads (aVR, aVL, and aVF), and
the unipolar precordial (chest) leads (VA: the needle was
placed immediately to the right of the sternum in the 4th
intercostal space; VB: the needle was placed just to the left of
the sternum in the 4th intercostal space; and VC; the needle
was positioned in the 5th intercostal space at the midaxillary
line). To avoid errors in the positioning of the leads, the
same individual consistently placed the electrodes on the
animals. The ECG was recorded using an ECG amplifier
(model 8811A, Hewlett-Packard Med. Inst., Waltham, MA,
USA) coupled to a 12-bit analogue-to-digital interface (DI-
720-USB, Dataq Instruments, Inc., Akron, OH, USA) at the
sampling rate of 3 KHz on an IBM personal computer with
the analysis performed by Windaq-Pro+ software (Dataq
Instruments, Inc., Akron, OH, USA). The ECG was recorded
for 2 minutes. The intervals and wavelengths (ms) were
calculated automatically using customized software following
wave identification and cursor placement. The ECG tracings
were consistently analyzed by the same individual, who was
blinded to the study protocol.The following ECG parameters
were examined: (1) RR interval (RRi), (2) P wave duration
(Pd), (3) PR interval (PR), (4) QRS duration (QRSd), (5) QT
interval (QT), and (6) corrected QT interval (cQT, defined
as the QT interval corrected for heart rate using Bazett’s
equation, where the corrected QTc was equal to QT (in s)/RR
(in s)1/2). In contrast to humans, the T wave in small rodents
is not well characterized and appears as a shoulder of the
QRS complex. Accordingly, to measure the QT interval, we
used the apex of the T wave, which can be determined with
high accuracy. The ECG parameters were determined from
each lead and were averaged. Additionally, the presence of
cardiac arrhythmias and atrioventricular or intraventricular
blockades, among other alterations, was analyzed by visual
inspection of ECG tracings by a blinded ECG specialist.
2.4. Long-Term Electrocardiographic Recordings in Freely
Moving Mice. After the third ECG recording, at the 6th
month of observation, the animals were reanesthetized with
tribromoethanol (250mg/kg, i.p.), and a pair of stainless steel
electrodes were implanted inside the subcutaneous tissue to
collect chronic recordings of conventional bipolar limb ECG
lead II. The animals were also cannulated with polyethylene
tubing placed in the jugular vein for drug administration.
After the surgical procedures, the animals were left to recover
in individual cages for at least 48–72 h.
After 48–72 h of surgical recovery and in the absence of
anesthesia, the electrodes were connected to an ECG ampli-
fier (model 8811A, Hewlett Packard, Waltham, MA, USA),
and the baseline ECG was sampled continuously (3 KHz) for
a period of 30 minutes with a personal computer (IBM/PC)
equipped with a 12-bit analogue-to-digital interface (DI-720-
USB, Dataq Instruments, Inc., Akron, OH, USA). All animals
were always recorded between 8:00AM and 5:00 PM in a
quiet condition and in a freelymoving state.The time series of
RR intervals derived from these chronic ECG recordingswere
used to study the cardiac autonomic modulation in heart rate
variability.
2.5. Heart Rate Variability Analysis. From the baseline chron-
ic ECG recordings (30 minutes), the RR interval time series
were derived automatically by the detection of the R wave
peaks using customized linear analysis software, which was
kindly provided by Dr. Alberto Porta (University of Milan,
Italy). The time series of the RR intervals were divided
into contiguous segments of 300 beats overlapping by half
(Welch protocol). After calculating themean and variance for
each segment, a model-based autoregressive spectral analysis
was performed, as described elsewhere [31, 32]. Briefly, a
model of the oscillatory components present in the stationary
segments of the beat-to-beat time series of the RR intervals
was calculated based on the Levinson-Durbin recursion, and
the order for the model was chosen according to Akaike’s
criterion [32]. This procedure allows for the automatic quan-
tification of the center frequency and power of each relevant
oscillatory component in the time series. The oscillatory
components were labeled as very low frequency (VLF), low
frequency (LF), or high frequency (HF) when the central fre-
quencies were within the bands of 0.01–0.10Hz, 0.10–1.00Hz,
or 1.00–5.00Hz, respectively [18].Thepower of the LF andHF
components of the heart rate variability was also expressed
in normalized units, which were obtained by calculating the
percentage of the LF and HF variability with respect to the
total power after subtracting the power of the VLF compo-
nent (frequencies < 0.10Hz). The normalization procedure
tends to minimize the effect of changes in the total power on
the absolute values of the LF and HF variabilities [31, 32].
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2.6. Pharmacological Autonomic Blockade. After 30 minutes
of baseline chronic ECG recording, half of the animals were
given an intravenous injection of atropine sulfate (1mg/kg,
i.v.) followed by an injection of propranolol (1mg/kg, i.v.)
15 minutes later, whereas the other half received injections
in the reverse sequence (propranolol followed by atropine
sulfate). This procedure allowed for the quantification of the
cardiac parasympathetic and sympathetic autonomic effects,
in the former and latter group, respectively, measured as
the differences between heart rate (HR) after atropine and
baseline HR (parasympathetic effect) or as the differences
between HR after propranolol and baseline HR (sympathetic
effect), as well as the measurement of intrinsic pacemaker
heart rate (IHR), quantified as the heart rate after the double
blockade with atropine sulfate followed by propranolol or
propranolol followed by atropine sulfate.
2.7. Histopathological Examination. At the end of the experi-
mental protocol, all animals were euthanized with an excess
dose of sodium thiopental (100mg/kg, resp., i.p.), and the
chest cavity was then opened to remove the heart for histo-
pathological analysis. To evaluate the extent of inflammatory
infiltration, tissue damage, fibrosis, and parasite nests, excised
hearts from all animals were cleaned in 0.9% saline solution
and fixed in phosphate-buffered 10% formalin solution for
48 h.
After embedding the samples in paraffin, five 5–7 𝜇m
thick longitudinal (four-chamber) sections of the hearts
were stained with hematoxylin-eosin and analyzed using an
upright lightmicroscope (Axiolab, Carl Zeiss Inc., Germany).
All regions of the hearts were examined by two blinded
observers. The inflammatory infiltration and parasite nests
were characterized using a semiquantitative approach and the
scoring system described by Chapadeiro et al. [33]. A global
myocardial inflammation score was defined for each animal
as the sum of the scores from different regions of the heart.
To quantify the fibrotic area in the myocardium, con-
tiguous longitudinal sections of the hearts were stained with
Picrosirius Red, which binds the collagen present in the tis-
sue matrix, and the slides were analyzed with polarized light
microscopy using KS300 software (Karl Zeiss, Inc., Ger-
many).
To enhance the visualization of parasite nests or antigens
in cardiac tissue, an immunohistochemistry technique based
on the detection of the diaminobenzidine (DAB-) derived
chromogenwas performed.The chromogenwas generated by
a secondary antibody labeled with peroxidase, which binds
to a primary antibody against T. cruzi antigens. After anti-
body labeling, peroxidase reaction, and costaining with hem-
atoxylin, slides were analyzed with an upright light micro-
scope (Axiolab, Carl Zeiss Inc., Germany).
2.8. Quantification of Serum Levels of Cytokines. At the end
of the experimental protocol, serum samples for each animal
were collected by means of cardiac puncture to perform
cytokine profiling (IFN-𝛾, TNF-𝛼, IL-2, IL-4, IL-5, and IL-10)
via ELISA or the cytometric bead array (CBA) technique.
Enzyme-Linked Immune Assay (ELISA). Serum concentra-
tions of IFN-𝛾 and IL-10 weremeasured by ELISA using pairs
of monoclonal antibodies in accordance with the manufac-
turer’s specifications (BD Pharmingen). Briefly, high-affin-
ity 96-well plates (Nunc, Roskilde, Denmark) were sensitized
with cytokine-specific monoclonal antibodies followed by
blocking with PBS containing 2% BSA (Sigma). The sera
and recombinant cytokines were then added, and the plates
were incubated for 4 h at room temperature. The plates were
washed and incubatedwith 1𝜇g/mLbiotinylated anticytokine
monoclonal antibody at 37∘C for 2 h followed by washing
and incubation with alkaline phosphatase-conjugated strep-
tavidin at 37∘C for 2 h.The reactionwas developed using diso-
dium-p-nitrophenyl phosphate (Sigma) in diethanolamine
buffer. Absorbance was measured at 405 nm in a microplate
reader (Bio-Rad, 2550 Reader EIA, CA, USA). The cytokine
concentration was calculated using a linear regression anal-
ysis of the absorbance values obtained for the recombinant
cytokines, and it was expressed as pg/mL. The sensitivity of
the tests ranged from 2 to 20 pg/mL.
2.8.1. Flow Cytometry Using a Cytometric Bead Array (CBA).
Measurement of the cytokines TNF-𝛼 and IL-2 (Th1 cytok-
ines) and IL-4 and IL-5 (Th2 cytokines) in serum samples was
performed using the cytometric bead array (CBA) kit (BD
Biosciences, USA) according to the manufacturer’s instruc-
tions. Briefly, 50𝜇L of bead populations with discrete fluo-
rescence intensities and coatedwith cytokine-specific capture
antibodies was added to 50 𝜇L of mice sera and 50𝜇L of phy-
coerythrin-conjugated anti-mouse Th1/Th2 cytokine anti-
bodies. Simultaneously, standards for each cytokine (0–
5000 pg/mL)weremixedwith cytokine capture beads and the
phycoerythrin-conjugated reagent. The vortexed mixtures
were incubated for 3 h. Beads were washed and analyzed
using flow cytometry (FACSCalibur, BD Biosciences, USA).
The quantity (pg/mL) of each cytokine was calculated using
CellQuest software (BD Biosciences, USA). Standard curves
were derived from the cytokine standards supplied with the
kit. The lower limit of detection ranged from 1 to 2.1 pg/mL
for different cytokines.
2.9. Parasite DNA Detection in the Blood and in the Heart
with Conventional PCR. For parasite DNA isolation from
the blood, total blood samples of mice were collected in
tubes containing 6M guanidine HCl with 0.2M EDTA (pH
8) (V/V). DNA was extracted using the phenol-chloroform-
isoamyl alcohol method according to Macedo et al. [34].
For parasite DNA isolation from the heart, half of the
hearts excised at the end of the experimental protocol were
homogenized, and DNA was extracted by the alkaline lysis
method.
PCR specific for T. cruzi was performed according to
Wincker et al. [35] using the following primers to amplify a
fragment of 330 bp: 121 (5󸀠-AAA TAA TGT ACG GG(G/T)
GAG ATG CAT GA-3󸀠) and 122 (5󸀠-GGT TCG ATT GGG
GTT GGT GTA ATA TA-3󸀠) from a nonvariant region of
the kinetoplast DNAminicircles of T. cruzi.The cycling con-
ditions were as follows: 95∘C for 5 minutes followed by 35
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Table 1: Electrocardiogram before treatment with pyridostigmine bromide. Electrocardiographical parameters (expressed as mean ± S.E.M.)
collected after five months follow-up in noninoculated control (Con) or T. cruzi-inoculated (Chg) anesthetized C57BL/6j mice before
treatment with pyridostigmine bromide (Pyrido) or vehicle (NT: nontreated animals).
Con-NT Con-Pyrido Chg-NT Chg-Pyrido
(𝑛 = 10) (𝑛 = 12) (𝑛 = 13) (𝑛 = 17)
RR (ms) 139.73 ± 5.22 150.83 ± 6.02 139.04 ± 5.62 133.35 ± 4.04
Pd (ms) 13.87 ± 1.50 13.8 ± 1.37 18.56 ± 0.51∗# 18.84 ± 0.72∗#
PR (ms) 38.83 ± 2.61 38.72 ± 2.28 40.64 ± 0.98 40.17 ± 1.29
QRSd (ms) 14.6 ± 1.86 13.61 ± 1.43 17.53 ± 1.08∗# 17.06 ± 1.00∗#
QT (ms) 20.74 ± 2.26 17.14 ± 1.60 22.28 ± 0.96∗# 21.2 ± 1.01#
cQT (ms1/2) 1.74 ± 0.51 1.42 ± 0.50 1.9 ± 0.08∗# 1.84 ± 0.09#
RR: RR interval; Pd: P wave duration; PR: PR interval; QRSd: QRS complex duration; QT: QT interval; cQT: corrected QT interval; ms: milliseconds; ∗𝑃 <
0.05 versus Con-NT; and #𝑃 < 0.05 versus Con-Pyrido.
Table 2: Electrocardiogram after treatment with pyridostigmine bromide. Electrocardiographical parameters (expressed as mean ± S.E.M.)
collected at the 6thmonth of observation and after onemonth of treatment (from the 5th to 6thmonth of infection) in noninoculated control
(Con) or T. cruzi-inoculated (Chg) anesthetized C57BL/6j mice treated with pyridostigmine bromide (Pyrido) or vehicle (NT: nontreated
animals).
Con-NT Con-Pyrido Chg-NT Chg-Pyrido
(𝑛 = 10) (𝑛 = 12) (𝑛 = 10) (𝑛 = 17)
RR (ms) 137.56 ± 3.37 141.05 ± 5.38 152.54 ± 5.01∗ 152.98 ± 12.93
Pd (ms) 14.01 ± 1.53 13.38 ± 1.51 18.68 ± 0.52∗&# 14.63 ± 0.53
PR (ms) 37.93 ± 1.96 44.38 ± 2.51∗ 45.45 ± 2.22∗ 43.2 ± 0.99
QRSd (ms) 14.45 ± 1.39 13.47 ± 1.37 15.04 ± 0.53 14.5 ± 0.41
QT (ms) 17.77 ± 1.87 17.35 ± 1.38 22.47 ± 1.04∗# 18.21 ± 0.59
cQT (ms1/2) 1.51 ± 0.51 1.49 ± 0.47 1.83 ± 0.09∗&# 1.51 ± 0.06
RR: RR interval; Pd: P wave duration; PR: PR interval; QRSd: QRS complex duration; QT: QT interval; cQT: corrected QT interval; ∗𝑃 < 0.05 versus Con-NT;
ms: milliseconds; &𝑃 < 0.05 versus Chg-Pyrido; and #𝑃 < 0.05 versus Con-Pyrido.
cycles at 95∘C for 1 minute and 65∘C for 1 minute. The pro-
ducts of the reaction were revealed by electrophoresis in
a 6.0% polyacrylamide gel and stained with silver nitrate,
which was photographed with a digital camera.
2.10. Statistical Analysis. All numerical data are expressed
as the means (±S.E.M.), whereas the semiquantitative data
from the histological examinations are expressed as themedi-
ans and the 25th and 75th percentiles. According to the nor-
mality and variance homogeneity of the distribution, a para-
metric statistic, such as two-way ANOVA followed by Tukey’s
multiple comparison test, or a nonparametric test, such as
theMann-Whitney test, was performed. Categorical variables
were analyzed using the Fisher exact test. All statistical calcu-
lations were performed using SigmaStat 2.0.3 software (SPSS
Inc., Chicago, IL, USA). The differences were considered
significant when 𝑃 < 0.05.
3. Results
Parasite detection in peripheral tail blood samples by the
microhematocrit technique performed on the 12th day after
infection was positive for all T. cruzi-inoculated animals and
negative for all control noninfected mice.
Electrocardiographical parameters measured in the first
ECG recording (ECG1) at the beginning of the experimen-
tal protocol before T. cruzi inoculation and treatment did
not show any significant difference among all experimental
groups, as expected. However, after five months of infection
and before the pyridostigmine bromide treatment, chagasic
animals (from Chg-NT and Chg-Pyrido groups) presented
significant elongations of Pd, QRSd, QT, and cQT (Table 1),
indicating a global functional disturbance of heart.
Interestingly, as shown in Table 2, after one month of the
pyridostigmine bromide treatment and six months of infec-
tion, Chg-Pyrido mice presented a significant reduction in
Pd (an atrial parameter) and cQT (a ventricular parameter),
suggesting an improvement in the electrical function of
the heart. In contrast, in Chg-NT mice, most of the ECG
parameters were significantly different compared to Con-NT
mice. It is worth noting that, in the Con-Pyrido group, a
significant increase in PR was observed, as expected, because
pyridostigmine bromide might be increasing vagal neural
transmission in the atrioventricular node, with a consequent
reduction in the conduction velocity of the action potential.
These results suggest that pyridostigmine bromide treatment
can be effective in improving electrical disorders induced by
chronic chagasic cardiomyopathy.
The results of heart rate variability analysis in time-
(variance) and frequency-domain (spectral) parameters are
shown in Table 3. A significant reduction in the absolute
values of total variability (variance) and the spectral compo-
nents VLF, LF, and HF was observed in Chg-NT mice com-
pared toCon-NT andCon-Pyridomice.The LF andHF com-
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Table 3: Heart rate variability after treatment with pyridostigmine bromide. Heart rate variability parameters (expressed as mean ± S.E.M.)
collected at the 6thmonth of observation and after onemonth of treatment (from the 5th to 6thmonth of infection) in noninoculated control
(Con) or T. cruzi-inoculated (Chg) freely moving C57BL/6j mice treated with pyridostigmine bromide (Pyrido) or vehicle (NT: nontreated
animals).
Con-NT Con-Pyrido Chg-NT Chg-Pyrido
(𝑛 = 9) (𝑛 = 9) (𝑛 = 9) (𝑛 = 12)
RR (ms) 117.97 ± 3.97 112.67 ± 4.14 104.27 ± 4.32 113.74 ± 4.33
HR (bpm) 516.81 ± 8.35 543.57 ± 9.06 590.61 ± 9.82 539.07 ± 8.76
Variance (ms2) 218.61 ± 12.35 148.96 ± 9.91 32.13 ± 5.12∗& 63.57 ± 6.11
VLF (ms2) 106.06 ± 8.93 69.37 ± 7.23 11.76 ± 2.84∗& 22.60 ± 3.90
LF (ms2) 57.84 ± 6.28 52.31 ± 6.23 11.10 ± 3.77∗ 21.99 ± 5.09
LF (nu) 51.83 ± 4.13 56.24 ± 4.09 47.80 ± 4.57 39.25 ± 4.91
HF (ms2) 54.71 ± 6.86 27.19 ± 4.44 9.01 ± 3.19∗& 18.78 ± 3.53
HF (nu) 47.54 ± 4.11 41.80 ± 3.97 48.05 ± 4.49 58.70 ± 4.86
LF/HF 2.31 ± 1.53 4.04 ± 1.48 2.60 ± 1.54 2.92 ± 2.01
RR: RR interval; HR: heart rate; VLF: very low frequency spectral component; LF: low frequency spectral component; HF: high frequency spectral component;
ms: milliseconds; bpm: beats per minute; nu: normalized units; ∗𝑃 < 0.05 versus Con-NT; and &𝑃 < 0.05 versus Chg-Pyrido.
ponents expressed in normalized units and the LF/HF ratio
were not different from Con-NT mice. In contrast, chagasic
mice treated with pyridostigmine bromide (the Chg-Pyrido
group) presented values of variance and VLF andHF spectral
components that were significantly higher compared to Chg-
NT mice, suggesting an improvement of some autonomic
parameters that changed during chronic chagasic cardiomy-
opathy (Table 3).
The autonomic dysfunction observed in the heart rate
variability analysis of Chg-NT mice and its improvement
in Chg-Pyrido mice was confirmed by pharmacological
autonomic blockade with atropine sulfate or propranolol.The
use of these autonomic blockers showed that vagal para-
sympathetic effects significantly decreased without a change
in sympathetic effects in Chg-NT mice compared with Con-
NT mice (Figure 1). Chagasic mice treated with pyridostig-
mine bromide showed values of vagal parasympathetic effects
that were significantly higher compared to Chg-NT mice
and similar to those found in Con-NT mice (Figure 1).
Additionally, noninfected control mice treated with pyri-
dostigmine bromide showed vagal parasympathetic effects
that markedly increased without any changes in sympathetic
effects compared with Con-NT mice (Figure 1). No changes
in the intrinsic pacemaker heart rate (IHR) were found in any
of the experimental groups after the six-month observation
period.
The relative cardiac weight of Chg-NT mice was sig-
nificantly higher than that observed in the other groups
(Figure 2), indicating that cardiac hypertrophy was induced
by Chagas disease in mice and that pyridostigmine bromide
treatment was able to reverse or impair the development of
cardiac hypertrophy in chagasic mice.
A semiquantitative examination of cardiac inflammatory
infiltration indicated discrete to mild diffuse myocarditis
(average inflammatory score was equal to 0.5, 𝑃25% = 0.5,
and 𝑃75% = 0.5, 𝑃 < 0.0001 versus Con-NT), which was
observed in the atria (Figures 3(g) and 3(h)), the ventricles
(Figures 3(e) and 3(f)), and the neural ganglia (Figure 3(g))
in the CHG-NT mice in comparison to normal CON-NT
mice (Figures 3(a), 3(b), 3(c), and 3(d)), which presented no
inflammatory infiltration (average inflammatory score was
equal to 0.0, 𝑃25% = 0.0 and 𝑃75% = 0.0). In Chg-
Pyrido mice, reduced inflammatory infiltration, which was
categorized as very discrete to discrete (average inflammatory
score was equal to 0.125, 𝑃25% = 0.0, and 𝑃75% = 0.25,
𝑃 < 0.001 versus Chg-NT), was observed in the atria, the
ventricles (Figures 3(i), 3(j), 3(k), and 3(l)), and the neural
ganglia. As expected in this mouse model of chronic Chagas
disease, no amastigote nests in the myocardium were found
in either Chg-NT or Chg-Pyrido mice.
In different sections of the heart stained by Picrosirius
Red, the morphometry of fibrosis revealed a marked and dif-
fuse increase in the fibrotic area in both absolute (𝜇m2)
and relative (%) values in the Chg-NT group compared
to Chg-NT mice (Figure 4). Interestingly, Chg-Pyrido mice
presented significantly reduced fibrotic areas in all cardiac
chambers (Figure 4) compared to Chg-NT mice. Despite
these reduced values, the fibrotic areas were still larger than
those found in Con-NT mice (Figure 4).
The serum levels of the cytokines IL-2, IL-4, IL-5, and
TNF-𝛼, measured with the CBA technique, did not reveal any
change in any of the experimental groups. In fact, the serum
levels of IL-2 and IL-4 were undetectable, with values near
0 pg/mL. However, using the ELISA technique, serum levels
of IFN-𝛾were significantly higher in Chg-NTmice compared
to Chg-Pyrido mice (𝑃 < 0.05). No IFN-𝛾 was detected in
Con-NT mice. Serum levels of IL-10, measured with ELISA
technique, were significantly higher in both Chg-NT and
Chg-Pyrido mice compared to Con-NT mice (𝑃 < 0.05).
No differences were found in the serum IL-10 levels between
Chg-NT and Chg-Pyrido mice (Figure 5).
The immunohistochemical technique using peroxidase to
label T. cruzi parasite nests or antigens revealed a complete
absence of parasites in control noninfected mice, whereas
T. cruzi labeling was positive for 62.50% of Chg-NT and
81.81% of Chg-Pyrido mice (𝑃 = 0.603, not significant using
the Fisher exact test). The parasite antigens were diffusely
distributed throughout the heart tissue (Figure 6).
Using a conventional PCRmethod to detect parasiteDNA
in blood andheart during the chronic phase ofChagas disease
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Figure 1:Heart rate responses to pharmacological autonomic blockade.Heart rate responses (ΔHR) to propranolol (sympathetic effect) (Panel
(a)) or to atropine sulfate (vagal parasympathetic effect) (Panel (b)) expressed asmean± S.E.M. andmeasured at the 6thmonth of observation
and after one month of treatment (from the 5th to 6th month of infection) in noninoculated control (Con) or in T. cruzi-inoculated (Chg)
freely moving C57BL/6j mice treated with pyridostigmine bromide (Pyrido) or vehicle (NT: nontreated animals). (∗𝑃 < 0.05 versus Con-NT;
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Figure 2: Relative cardiac weights after treatment with pyridostig-
mine bromide. Relative cardiac weights (in mg/g) expressed as
mean ± S.E.M. calculated at the 6th month of observation and after
one month of treatment (from the 5th to 6th month of infection)
in noninoculated control (Con) or in T. cruzi-inoculated (Chg)
C57BL/6j mice treated with pyridostigmine bromide (Pyrido) or
vehicle (NT: non treated animals). (∗𝑃 < 0.05 versus Con-NT and
&
𝑃 < 0.05 versus Chg-NT).
in mice, a complete absence of parasite DNA in noninfected
control mice was observed, whereas T. cruziDNA was found
in 16.67% and 42.9% (𝑃 = 0.559) in the blood of Chg-NT
andChg-Pyridomice, respectively, and in 72.73% and 86.67%
(𝑃 = 0.614) of heart samples from Chg-NT and Chg-Pyrido
mice, respectively.
4. Discussion
To our knowledge, the present study is the first to analyze the
effects of the deliberate potentiation of cholinergic signaling
using pyridostigmine bromide, an anticholinesterase agent,
during the chronic phase of experimental Chagas disease
in mice. Furthermore, this study evaluated the effects of
pyridostigmine bromide treatment on electrocardiographic,
autonomic, histopathological, immunoinflammatory, and
parasitological parameters of Chagas disease.
Thepresent study is, to our knowledge, the first to demon-
strate autonomic dysfunction induced by chronic Chagas
disease in an experimental mouse model. This dysfunction
was characterized by a marked reduction in heart rate
variability, with reduced variance (time-domain parameter)
and the VLF, LF, and HF components (frequency-domain
parameters) of heart rate variability, as well as a concurrent
reduction in the cardiac vagal effect, without an apparent
change in sympathetic effects, as measured by pharmacolog-
ical blockade in chronic control chagasic animals. Only mor-
phological reports describing the ganglia and nerve lesions in
chagasic mice have been published in the literature [36].This
finding follows our previous report of a similar autonomic
dysfunction inmicewith acuteChagas disease [18].This auto-
nomic dysfunctionwas accompanied by electrocardiographic
changes associated with mild diffuse inflammatory infiltra-
tion of mononuclear cells as well as fibrosis and hypertrophy
in the atrial and ventricular myocardium and the elevation
of IFN-𝛾 and IL-10 in the blood serum of wild-type and
untreated chagasic C57BL/6j mice, which confirms the pres-
ence of chronic myocarditis six months following infection
with T. cruzi. This increase in serum levels of IFN-𝛾 and IL-
10 in chronic chagasic mice matches similar previous reports
in human beings [37–39]. Additionally, parasite antigens and
DNA were detected by immunohistochemical labeling in the
heart and by PCR in blood and heart, respectively, reinforcing
the role played by parasites in inducing and/or maintaining
chronic infection. Because our findings are consistent with
previous observations in hamsters, rabbits, dogs, and humans
during the chronic phase of Chagas disease [10, 40], the
mouse model used here appears to represent a suitable tool
for future experimental studies in Chagas heart disease.
During the chronic phase of Chagas heart disease, this
report revealed a significant increase in cardiac vagal para-
sympathetic autonomic modulation associated with a signifi-
cant reduction of inflammatory infiltration in the myocar-
dium of infected mice treated with pyridostigmine bromide
during the last month of a six-month observation period.







Figure 3: Cardiac histopathology after treatment with pyridostigmine bromide. Photomicrographs of cardiac sections stained with H-E.
Panels (a) and (b): ventricular sections from a control nontreated mouse. Panels (c) and (d): ventricular sections from a pyridostigmine
bromide-treated control mouse. Panels (e) and (f): ventricular sections from a chagasic nontreated mouse. Panels (g) and (h): atrial sections
from a nontreated chagasic mouse showing, respectively, a ganglionitis and neuritis focus. Panels (i), (j), (k), and (l): different ventricular
sections from a chagasic mouse treated with pyridostigmine bromide. Note the lower inflammatory infiltration into heart tissues from a
chagasic mouse treated with pyridostigmine bromide. (Left panels: magnification = 100x; right panels: magnification = 200x.)






























































































Figure 4: Cardiac fibrosis after treatment with pyridostigmine bromide. Fibrotic areas (in 𝜇m2) expressed as mean ± S.E.M. for the right
(Panel (a)) and left (Panel (b)) atria, the right (Panel (c)) and left (Panel (d)) ventricles, and the atrioventricular septum (Panel (e)), measured
after Picrosirius Red staining at the 6th month of observation and after one month of treatment (from the 5th to 6th month of infection) in
noninoculated control (Con) or in T. cruzi-inoculated (Chg) C57BL/6j mice treated with pyridostigmine bromide (Pyrido) or vehicle (NT:
nontreated animals). (∗𝑃 < 0.05 versus Con-NT; &𝑃 < 0.05 versus Chg-Pyrido; and #𝑃 < 0.05 versus Con-Pyrido).
Because pyridostigmine bromide is an anticholinesterasic
agent, which increases the bioavailability of acetylcholine in
the synaptic varicosities, the increase in cardiac vagal para-
sympathetic autonomic function, demonstrated by the higher
heart rate variability and cardiac vagal effect, was expected
and was verified after treatment. This vagal stimulation effect
of pyridostigmine bromide confirms previous reports in
other experimental contexts [41].
The anti-inflammatory effect of pyridostigmine bromide
was associatedwith amarked reduction ofmyocardial fibrosis
and hypertrophy. Serum levels of IFN-𝛾 also decreased,
whereas TNA-𝛼 trended to decrease, both of which are Th1
proinflammatory cytokines, without any change in the aug-
mented serum levels of IL-10.
The combined analysis of these results suggests that pyri-
dostigmine bromide may act on the heart, at least partially



























































Figure 5: Serum cytokines after treatment with pyridostigmine bromide. Serum levels (in pg/mL) expressed as mean ± S.E.M. of tumor
necrosis factor-𝛼 (TNF-𝛼: Panel (a)), interleukin-5 (IL-5: Panel (b)) measured by the cytometric bead array technique, interferon-𝛾 (IFN-𝛾:
Panel (c)), and interleukin-10 (IL-10: Panel (d)) measured by ELISA at the 6th month of observation and after one month of treatment (from
the 5th to 6th month of infection) in noninoculated control (Con) or T. cruzi-inoculated (Chg) C57BL/6j mice treated or not (NT) with
pyridostigmine bromide (Pyrido). (∗𝑃 < 0.05 versus Con-NT; &𝑃 < 0.05 versus Chg-Pyrido; and #𝑃 < 0.05 versus Con-Pyrido).
increasing the vagal parasympathetic activity, via the accu-
mulation of acetylcholine in themyocardium.This accumula-
tion was confirmed by improvements in heart rate variability
and vagal parasympathetic effect, which, acting on immune
cells, may exert immunomodulatory effects, thereby shifting
the immune response toward the predominance of an anti-
inflammatory response.
These new findings in the chronic Chagas disease context
reinforce the idea of an intimate interplay between the
immune and autonomic nervous systems and the potential
use of parasympathetic stimulation to treat chagasic myocar-
ditis [18, 23]. Additionally, the improvement of cardiac
inflammation, fibrosis, and hypertrophy in pyridostigmine
bromide-treated chronic chagasic animals suggests that the
decrease of vagal autonomic function due to ganglionic neu-
ronal lesions and denervation, which occur precociously dur-
ing the acute phase, may play an important immunomodula-
tory role in the increased Th1 immune response and inflam-
matory infiltration, as verified during the chronic phase of the
disease.
Even though our results support the immunomodulatory
role played by the cholinergic vagal parasympathetic nervous
system in the heart, we cannot rule out a possible role
of pyridostigmine bromide in increasing local acetylcholine
levels via its release from nonneural local structures, such
as endothelial cells, cholinergic lymphocytes, and cardiomy-
ocytes [42]. In fact, these nonneural sources of acetyl-
choline, potentiated by pyridostigmine bromide treatment,
may explain the substantial improvement in ECG abnormal-
ities, inflammation, fibrosis, and hypertrophy observed in
both ventricles of the heart, which are poorly innervated by
vagal parasympathetic fibers.
Data from the immunohistochemical labeling of T. cruzi
antigens and T. cruzi DNA detection by PCR showed that
parasites are present in the heart tissue and blood of the
chagasicmice sixmonths after infection, confirming previous
reports [38, 43]. The number of animals positive for parasite
antigens or DNA did not differ between pyridostigmine
bromide-treated and nontreated chagasic animals. The per-
sistence of the parasite in the chronic phase, even at a very













Figure 6: Immunohistochemistry for parasite antigens. Photomicrographs from left ventricular sections stained with T. cruzi antigens by
peroxidase reaction. Panels (a) and (d): control nontreated mouse. Panels (b) and (e): chagasic nontreated mouse. Panels (c) and (f): chagasic
mouse treated with pyridostigmine bromide. Top panels: magnification = 100x; bottom panels: magnification = 200x. Note the gray color
labeling T. cruzi antigens throughout the sections in Panels (b), (c), (e), and (f).
low level, seems to play an important role in the pathogenesis
of chronic Chagas disease because the low parasite load
may continuously stimulate an immune response [38, 43].
Although antigens or DNA from T. cruzi were detected in
the present study, no parasite pseudocysts or amastigote
forms were observed in the heart tissue in either treated or
nontreated chagasic mice. This lack of entire parasites at the
site of cardiac lesions suggests the possibility of a remote
niche for the parasites, such as smooth muscle cells, adipo-
cytes, or skeletal muscle cells [43].
In conclusion, our results support the notion that auto-
nomic dysfunction is a primary cause of the pro-/anti-inflam-
matory imbalance observed in inflammatory diseases, favor-
ing the shift of immune response toward the predominance of
proinflammatory response, thereby contributing to the path-
ogenesis of these diseases in general and Chagas heart disease
in particular. Additionally, our findings showed the potential
beneficial effects of anticholinesterasic agents, particularly
pyridostigmine bromide, in increasing cardiac autonomic
modulation and reducing inflammatory response to the
heart.
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